Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval entities : Eli lilly and company save search
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
fda drug approval treatment
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-17 (Crawled : 18:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.71%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
ebglyss dermatitis approval
Global Biosimilars Business and Investment Opportunities 2023: Attractive Approval Numbers Present Fertile Ground for New Entrants
Published: 2023-04-18 (Crawled : 18:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.17%
H: 0.34%
C: -0.83%
CHRS | $2.03 -6.88% -7.39% 720K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.45%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.05%
H: 0.77%
C: 0.5%
business approval global
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
Published: 2023-01-19 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.16%
H: 0.6%
C: -0.27%
drug approval response food
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy
Published: 2022-12-19 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.57%
H: 0.53%
C: -0.01%
EGRX | $4.58 -3.98% -4.15% 95K
|
Health Technology
|
| O: 3.31%
H: 0.46%
C: -0.89%
pemfexy fda pharmaceuticals approval
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2022-06-27 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 3.36%
H: 0.35%
C: -0.71%
tyvyt treatment approval china
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma
Published: 2022-06-21 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 5.74%
H: 0.0%
C: 0.0%
tyvyt treatment approval china cell carcinoma
Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
bevagen approval food drug
Global Panic Disorders Market Insights | Size | Shares | Trends | Growth | Industry Analysis [2020-2030] Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks. PET-CT Scanner Devices Market: Competitive Landscape Analysis With Forecast by 2031 Wilmington, Delaware: According to the report, the global PET-CT scanner devices market was valued over US$ 200 Mn in 2020 and is projected to expand at a CAGR of ~3% from 2021 to 2031. Portal Hypertension Market Insights | Current Trends | Growth Opportunity | Global Industry Analysis [2020-2030] At present, treatment options for portal hypertension is limited due to the dearth of approval of specialized drugs. Spatial Genomics & Transcriptomics Market to Experience Significant Growth by 2027 Wilmington, Delaware: The spatial genomics & transcriptomics market is prognosticated to bring profitable growth during the assessment period of 2019-2027. Teleradiology Services Market to Make Great Impact in Near Future by 2031 Wilmington, Delaware: According to the report, the global teleradiology services market was valued over US$ 6.4 Bn in 2020. Anti-depressants Drugs and Therapies Market to Witness a Pronounce Growth by 2025 Wilmington, Delaware: Anti-depressants medications lower the symptoms of depression, dysthymia, chronic depression, and anxiety disorders. B-Cell Non-Hodgkin’s Lymphoma (NHL) Market to Offer Ample Growth Opportunities by 2027 Wilmington, Delaware: Non-Hodgkin’s lymphoma is a group of heterogeneous proliferative malignancies. Heightening Healthcare Spending Opening Growth Avenues for Collateral Ligament Stabilizer System Market, Reaching US$ 3.5 Billion in 2032: Fact.MR Study Fact.MR – A Market Research and Competitive Intelligence Provider: The global collateral ligament stabilizer system market is expected to reach US$ 3.5 Billion by the end of the 2022-2032 forecast period, growing at a CAGR of 6.1%, concludes a recently published report by Fact.MR. Breast Cancer Liquid Biopsy Market Trends, Growth, Analysis and Future Scope, 2026 Wilmington, Delaware: A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Cerebral Palsy Market Size, Shares, Trends and Growth | Global Industry Analysis [2020-2030] The global cerebral palsy market is picking up steam due to increasing awareness about the condition amongst parents. Continuous Glucose Monitoring Market: Competitive Research and Precise Outlook 2021 to 2028 Wilmington, Delaware: The global continuous glucose monitoring market depicts the presence of a large competitive vendor landscape, says Transparency Market Research on the basis of a newly research report. Crow’s Feet Market Key Trends and Opportunity Analysis up to 2026 Albany NY, United States: The demand within the global crow’s feet market has been escalating on account of vital advancements in the field of dermatology in recent times. HIV Associated Lipodystrophy Syndrome Market Insights | Global Industry Analysis [2020-2030] HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus -infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Global Mail Service Pharmacy Market | Size | Shares | Trends | Growth | Forecast [2020-2030]
Published: 2022-06-03 (Crawled : 06:00) - biospace.com/
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.4%
H: 4.05%
C: -1.35%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.25%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 2.29%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
lipodystrophy treatment research system active services report service growing hiv profitable hypertension genomics expected virus approval cancer growth group market breast cancer infections
Global Pharmaceutical API Manufacturing Market Report 2022-2030: Stringent Regulations for Approval of Pharmaceutical Drugs Restraining Growth
Published: 2022-04-12 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.86%
H: 1.21%
C: 1.21%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.16%
H: 0.22%
C: 0.22%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.48%
H: 0.09%
C: -0.68%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.77%
H: 0.99%
C: 0.49%
ALB | News | $115.27 0.93% -0.23% 2.2M
|
Process Industries
|
| O: 1.31%
H: 2.06%
C: -1.76%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.31%
H: 0.74%
C: -1.18%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -3.25%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -2.32%
H: 0.43%
C: -0.55%
report approval growth market drug
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma
Published: 2022-04-06 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
Published: 2022-04-06 (Crawled : 05:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment test diagnostic approval one therapy
Global Generic Injectables Market Research Report 2022: Expiration of Branded Drug Patents & Rising Approvals for Generic Injectable Drugs
Published: 2022-03-15 (Crawled : 23:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
als drug patent research approval report
QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation
Published: 2022-02-11 (Crawled : 13:30) - globenewswire.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: 0.76%
H: 3.98%
C: -0.95%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
qbrexza approval corporation one milestone
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published: 2022-01-24 (Crawled : 12:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
Published: 2022-01-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval system therapy
Eli Lilly’s Two-Year Ambition Includes Alzheimer’s Approvals
Published: 2021-12-15 (Crawled : 19:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 4.7%
H: 0.0%
C: 0.0%
alzheimer als approval alzheimer’s alzheimer's
Global Immunotherapy Drugs Markets 2021-2026 - Launch of NG Immunotherapies / COVID-19 as Growth Catalyst / Approval of Novel Immunotherapy Drugs / Surge in Adoption of Car T-Cell Therapies
Published: 2021-10-28 (Crawled : 18:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 2.63%
C: 1.28%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.83%
H: 1.2%
C: 0.32%
covid immunotherapy therapy drug growth approval t-cell car-t
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Published: 2021-10-13 (Crawled : 23:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.55%
H: 1.64%
C: 1.01%
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: 0.76%
H: 1.21%
C: 0.76%
fda risk cancer breast cancer approval diagnostic
Oncomine Dx Target Test Receives MHLW Approval as a Companion Diagnostic for Eli Lilly's RET-Inhibitor in Non-Small Cell Lung Cancer in Japan
Published: 2021-09-10 (Crawled : 12:15) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 0.49%
H: 0.71%
C: 0.07%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.92%
H: 0.7%
C: -1.11%
lung cancer test cancer approval diagnostic
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.